The Journal of Pharmacology and Experimental Therapeutics, 303(1), 314-22. American Society for Pharmacology and Experimental Therapeutics Hough, L H, Nalwalk, J B, Stadel, R, Timmerman, H, Leurs, R, Paria, B C, Wang, X W & Dey, S K 2002, ' Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-p yrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors ', The Journal of Pharmacology and Experimental Therapeutics, vol. 303, no. 1, pp. 314-22 . https://doi.org/10.1124/jpet.102.036251